179 results
Page 6 of 9
FWP
7tprth
18 Jul 18
Free writing prospectus
8:15am
8-K
EX-99.1
dobsit
17 Jul 18
Cellectar Reports 94% Reduction in Overall Tumor Volume in Waldenstrom Macroglobulinemia Patient in Phase 2 CLR 131 Clinical Study
4:05pm
8-K
EX-99.1
q3chfkrcki xhi
13 Jul 18
Cellectar Announces 1-for-10 Reverse Stock Split
4:15pm
8-K
EX-99.1
b848bc ps1ocrfk3
9 Jul 18
Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing’s Sarcoma
4:01pm
8-K
EX-99.1
7rsfr5 c5
28 Jun 18
Cellectar Announces Expansion of Diffuse Large B-Cell Lymphoma Cohort in CLR 131 Phase 2 Trial
4:02pm
8-K
EX-99.1
6yvcdox
7 Jun 18
Cellectar Granted U.S. Patent for the Treatment of Various Cancers and Cancer Stem Cells with CLR 131
4:01pm
8-K
EX-99.1
3mwkpamg6 pa9esxh4
6 Jun 18
FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Rhabdomyosarcoma
4:01pm
8-K
EX-99.1
4ch m57ia2ql9
11 May 18
Cellectar Reports Recent Corporate Highlights and 2018 First Quarter Financial Results
8:30am
8-K
EX-99.1
x68ya8vtya sn
9 May 18
Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma
4:03pm
8-K
EX-99.1
voqw6ye9s85dwo
2 May 18
Cellectar Receives Rare Pediatric Disease Designation for CLR 131 to Treat Neuroblastoma
4:03pm
8-K
EX-99.1
z3tbv7a 2k1f
17 Apr 18
Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating Efficacy of Fractionated Injections of CLR 131 in Multiple Myeloma
12:00am